Author Archive

Parkinson’s Patients Face Treatment Delays

A guest blog by Dr. Michael Rezak, M.D., Ph.D. During a recent visit with one of my Parkinson’s patients, we decided he was a good

Read More

Innovation, Access Issues Dominate Biologics & Biosimilars Summit

“I thought maybe I wasn’t very good athletically.”  That was iconic Olympic gold medalist Jackie Joyner-Kersee’s recollection of her first experience with asthma attacks. Joyner-Kersee

Read More

Cost Sharing is Costing Skin Patients their Medication

After spending time and money to see a dermatologist, many patients with acne fail to fill their prescription. Cost sharing is the culprit, according to

Read More

FDA Opens Door to Pregnant Women in Clinical Trials

Nearly 4 million babies are born each year in the United States.  Yet physicians can have remarkably limited data about treating mothers’ health conditions during

Read More

***PRESS RELEASE*** INSTITUTE FOR PATIENT ACCESS STATEMENT ON ICER’S MIGRAINE DRAFT EVIDENCE REPORT

WASHINGTON – Today, the non-profit Institute for Patient Access made the following statement regarding the Institute for Clinical and Economic Review’s (ICER) draft evidence report

Read More

***PRESS RELEASE*** Nationwide, Health Plans Rejected Almost 80,000 Claims for High Cholesterol Treatment

National health plan report card analyzes 2017 PCSK9 inhibitor claims for managed care organizations WASHINGTON – The non-profit Institute for Patient Access released a new Health Plan

Read More

Patents, Progress & Patient Access

Could a recent memorandum from the U.S. Patent and Trademark Office impact treatment options for patients?  Washington, DC’s nonprofit Bipartisan Policy Center says: Yes. As

Read More

***PRESS RELEASE*** New Paper “The ICER Myth” Explores Drawbacks of ICER’s Evidence Reports and Their Impact on Patients

ICER has come under scrutiny for its methodology and calculations that impact patient access to approved therapies. WASHINGTON – The nonprofit Institute for Patient Access (IfPA)

Read More

“The ICER Myth” Questions One-Size-Fits-All Approach to Drug Valuation

What is innovative medicine worth to patients?  It depends on which patient you ask.  The disease a patient suffers from, its symptoms and their impact

Read More

What Your Pharmacist Can’t Tell You

Patients overpay for their prescriptions 23 percent of the time, a recently released study from the University of Southern California found.  What’s worse – some

Read More
Back to Top